Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Rivaroxaban in atrial fibrillation

Authors Giorgi MA, Miguel LS

Received 8 February 2012

Accepted for publication 27 June 2012

Published 30 August 2012 Volume 2012:8 Pages 525—531

DOI https://doi.org/10.2147/VHRM.S19825

Review by Single-blind

Peer reviewer comments 2

Mariano A Giorgi,1,2 Lucas San Miguel3

1Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”, 2Department of Pharmacology, School of Medicine, Universidad Austral, 3Department of Cardiology and Cardiovascular Surgery, FLENI, Buenos Aires, Argentina

Abstract: Warfarin is the traditional therapeutic option available to manage thromboembolic risk in atrial fibrillation. The hemorrhagic risk with warfarin depends mainly on the international normalized ratio (INR). Data from randomized controlled trials show that patients have a therapeutic INR (2.00–3.00) only 61%–68% of the time while taking warfarin, and this target is sometimes hard to establish. Many compounds have been developed in order to optimize the profile of oral anticoagulants. We focus on one of them, rivaroxaban, comparing it with novel alternatives, ie, dabigatran and apixaban. The indication for rivaroxaban in nonvalvular atrial fibrillation was evaluated in ROCKET-AF (Rivaroxaban-once daily, Oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation). In this trial, rivaroxaban was associated with a 12% reduction in the incidence of the primary endpoint compared with warfarin (hazard ratio 0.88; 95% confidence interval [CI] 0.74–1.03; P < 0.001 for noninferiority and P = 0.12 for superiority). However, patients remained in the therapeutic range for INR only 55% of the time, which is less than that in RE-LY (the Randomized Evaluation of Long-Term Anticoagulation Therapy, 64%) and in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation, 66%). This shorter time spent in the therapeutic range has been one of the main criticisms of the ROCKET-AF trial, but could actually reflect what happens in real life. In addition, rivaroxaban exhibits good pharmacokinetic and pharmacoeconomic properties. Novel anticoagulants are a viable and commercially available alternative to vitamin K antagonists nowadays for the prevention of thromboembolic complications in atrial fibrillation. Rivaroxaban is an attractive alternative, but the true picture of this novel compound in atrial fibrillation will only become available with more widespread use.

Keywords: atrial fibrillation, anticoagulants, rivaroxaban

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study

Frankova S, Jirsa M, Merta D, Neroldova M, Urbanek P, Senkerikova R, Spicak J, Sperl J

Therapeutics and Clinical Risk Management 2015, 11:1853-1861

Published Date: 17 December 2015

Blood and urine levels of heavy metal pollutants in female and male patients with coronary artery disease

Sponder M, Fritzer-Szekeres M, Marculescu R, Mittlböck M, Uhl M, Köhler-Vallant B, Strametz-Juranek J

Vascular Health and Risk Management 2014, 10:311-317

Published Date: 13 May 2014

Visceral obesity is not an independent risk factor of mortality in subjects over 65 years

Thomas F, Pannier B, Benetos A, Vischer UM

Vascular Health and Risk Management 2013, 9:739-745

Published Date: 22 November 2013

Perceptions of barriers to cardiac rehabilitation use in Brazil

Ghisi GLM, Santos RZ, Aranha EE, Nunes AD, Oh P, Benetti M, Grace SL

Vascular Health and Risk Management 2013, 9:485-491

Published Date: 30 August 2013

Diagnosis of carotid artery stenosis with oculopneumoplethysmography alone and in combination with MRA

Elias RM, Wald JT, Kallmes DF

Vascular Health and Risk Management 2012, 8:631-639

Published Date: 23 November 2012

The potential benefit of stem cell therapy after stroke: an update

Banerjee S, Williamson DA, Habib N, Chataway J

Vascular Health and Risk Management 2012, 8:569-580

Published Date: 10 October 2012

The prevention and regression of atherosclerotic plaques: emerging treatments

Kalanuria AA, Nyquist P, Ling G

Vascular Health and Risk Management 2012, 8:549-561

Published Date: 25 September 2012